Diversity in Clinical Trials – Background The Federal Drug Administration (FDA) issued non-compulsory guidance on clinical trial diversity to encourage diverse populations in clinical trials and improve the applicability of clinical trial results. The guidance recommends diverse clinical trial populations to better understand the safety and effectiveness of medical products across race, ethnicity, and gender.…
The Diversity Issue in Clinical Trials – an overview Pharmaceutical industry discussions on Diversity, Equity, and Inclusion (DEI) all end in the same place—the need to build patient trust. However, there are few suggestions about how to build this trust and little recognition that it will take time. Additionally, trust is only the first step…
Our team will be in San Francisco during the J.P. Morgan Healthcare Conference and is ready to meet with investors and industry leaders. We will also be taking part in the First Analysis Healthcare Technology Conference – 2023. Reach out to Gerald Finken or to David Stark to schedule a meeting!
Client A biopharmaceutical company sponsoring a Phase III clinical trial in the United States. Challenge The trial required the recruitment of patients with a neurological pain indication. The sponsor perceived a potential concern that patients had several alternative treatment options, including commercially available products, and therefore, may not be interested in a clinical study opportunity…
Fargo, ND, October 2022 RxE2 is happy to announce a recent investment from Badlands Capital. “I am so pleased to be working with Badlands Capital, especially since RxE2 is headquartered in Fargo, ND. The Badlands team truly understand what clinical trial innovation looks like and the magnitude of what RxE2 is and will accomplish, as we solve the recruitment, diversity,…
RxE2 is proud to be a member of the PQA, a non-profit organization with 250 diverse members across healthcare. Now more than ever we need to bring the practice of pharmacy into clinical trials. Incorporating PQA programs like Pharmacist Provided Care and Medication Use Quality will change the future outcomes for any clinical trial program…
Pharmacists demonstrate tremendous expertise in drug counseling and dispensation, so it seems undeniable that they should play a prominent role in clinical research. After all, clinical trials are designed to establish the safety and efficacy of drugs: a pharmacist’s specialty. However, pharmacists are rarely consulted in clinical trials. To remedy this issue, Founder and CEO…
We’ll be attending the annual meeting of NCPA in Kansas City, October 1 – 4. If you’re coming, let’s meet up! Our team on site will also be available at the CPESN USA booth #541 in the Exhibit Hall on Sunday, October 2, 2022 and on Monday, October 3, 2022 between 12:30 – 3:30 pm…
Pharmacists demonstrate tremendous expertise in drug counseling and dispensation, so it seems undeniable that they should play a prominent role in clinical research. Surprisingly, their skill sets are rarely used in clinical trials. That’s why Founder and CEO Gerald Finken created RxE2, a community-based decentralized trial technology company spearheaded by pharmacists, offering primary stakeholders their…
Fargo, ND , June 2 2022 – RxE2 announces the appointment of David Stark as Senior Director of Business Development. In his role as senior director of business development, Mr. stark will be in charge of exploring new opportunities for expansion and partnerships for RxE2. “We were looking for an individual with a wide range…